Femoston 28 tablets (Variations)

Femoston Composition:
estradiol tablet:
active ingredient: estradiol; 1 tablet contains micronized estradiol hemihydrate, which is equivalent to 1 mg estradiol; excipients: lactose monohydrate, hypromellose (HPMC 2910), corn starch, colloidal silicon dioxide, magnesium stearate; film coating: Opadry Y-1-7000 white (hypromellose (HPMC 2910), polyethylene glycol 400, titanium dioxide (E 171)) – for tablets containing 1 mg of estradiol.
estradiol and dydrogesterone tablet:
active substances: estradiol; dydrogesterone; 1 tablet contains micronized estradiol hemihydrate, which is equivalent to estradiol 1 mg micronized dydrogesterone 10 mg; excipients: lactose monohydrate, hypromellose (HPMC 2910), corn starch, colloidal silicon dioxide, magnesium stearate; film coating: Opadry II gray 85F27664 (polyethylene glycol 3350, talc (E 553b), polyvinyl alcohol, black iron oxide (E172), titanium dioxide (E 171)) – for tablets containing 1 mg of estradiol and 10 mg of dydrogesterone.

Pharmacotherapeutic group:
Drugs for the treatment of diseases of the genitourinary system and sex hormones. Combined preparations containing progestogens and estrogens for sequential use. ATX code G03F B08.

Indications:
Hormone replacement therapy (HRT) to eliminate symptoms caused by estrogen deficiency in menopausal women no earlier than 6 months after the last menstruation. Prevention of osteoporosis in postmenopausal women at high risk of fractures. Femoston should be used in patients only in case of intolerance or contraindications to the use of other drugs for the prevention of osteoporosis (see section “Peculiarities of use”). Experience in treating women over 65 years of age is limited.

Produced in Netherlands.